VANCOUVER, British Columbia--(BUSINESS WIRE)--Contextual Genomics Inc. (“Contextual”), developers of genomic cancer tests and computational systems, is pleased to announce it has received full accreditation from the Diagnostic Accreditation Program (DAP). Contextual is the first laboratory to receive full accreditation in Molecular Diagnostics from DAP.
“As molecular testing and bioinformatics analysis become more widely used in cancer diagnosis, high standards need to be set to ensure process quality and information accuracy. DAP’s rigorous review provides a great foundation for assuring patient safety as molecular testing develops in B.C.”
DAP, a program of the College of Physicians and Surgeons of British Columbia, assesses the quality of diagnostic services in the province. As part of the accreditation process, Contextual’s molecular testing and informatics systems were reviewed. Contextual is also accredited by the College of American Pathologists (CAP), and the Centres for Medicare and Medicaid Services (CMS) Clinical Laboratory Improvements Amendments (CLIA).
Chris Wagner, President and CEO of Contextual, stated, “We are pleased to be the first company to receive full accreditation in Molecular Diagnostics from the DAP. This accreditation, along with our CAP/CLIA accreditation is a testament of our commitment to the highest quality, accuracy and safety. With our global expansion of molecular analysis services, it is extremely important to Contextual to set a gold standard in diagnostics and systems approaches.”
Dr. David Huntsman, Chief Medical Officer of Contextual, commented “As molecular testing and bioinformatics analysis become more widely used in cancer diagnosis, high standards need to be set to ensure process quality and information accuracy. DAP’s rigorous review provides a great foundation for assuring patient safety as molecular testing develops in B.C.”
In addition to the cost-effective molecular cancer tests developed by Contextual Genomics, the company has grown its ability to deploy its testing and analytics globally. Its bioinformatics services are designed to be utilized by partner laboratories around the world. The Find-It™ cancer panel is a multiplex, next-generation sequencing genomic assay designed for rapid deployment into labs around the world. Find-It™ evaluates the mutation status of tumor DNA at more than 100 well-characterized positions, identifying the somatic mutations that have the greatest potential to impact treatment decisions. QA Nexus™ is a quality control system embedded into all Find-It™ assays and into Contextual’s bioinformatic pipeline.
About Contextual Genomics
Contextual Genomics (www.contextualgenomics.com) has developed cost-effective and clinically actionable molecular tests that guide diagnosis and treatment of cancer. These customized tests are designed to be offered by partner laboratories around the world with Contextual conducting bioinformatics services via a SaaS model. The collection of data via this robust network of partners and the use of machine-learning tools will allow Contextual Genomics to improve patient care through improved clinical trial enrollment and new treatment algorithms.
Contextual is managed by global leaders in cancer research and bioinformatics, who have unparalleled expertise in cancer genomics and the clonal evolution of cancer.
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.
For more information, contact:
Contextual Genomics
Chris Wagner
President and CEO
media@contextualgenomics.com
